Evidence map›Paper›PMID 30698484›Full record

ArticlemAbs

Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.

Nathan D Trinklein, Duy Pham, Ute Schellenberger, Ben Buelow, Andrew Boudreau, Priya Choudhry, Starlynn C Clarke, Kevin Dang, Katherine E Harris, Suhasini Iyer and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 100 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  17. Article
  18. Review
  19. The Evolving Applications of Bispecific Antibodies: Reaping the Harvest of Early Sowing and Planting New Seeds.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Nathan D Trinkleina Teneobio, Inc ., Menlo Park , CA , USA.
Duy Phama Teneobio, Inc ., Menlo Park , CA , USA.
Ute Schellenbergera Teneobio, Inc ., Menlo Park , CA , USA.ORCID 0000-0002-4809-9383
Ben Buelowa Teneobio, Inc ., Menlo Park , CA , USA.
Andrew Boudreaua Teneobio, Inc ., Menlo Park , CA , USA.ORCID 0000-0002-0016-4561
Priya Choudhryb Department of Laboratory Medicine , University of California , San Francisco , CA , USA.ORCID 0000-0002-4438-1576
Starlynn C Clarkea Teneobio, Inc ., Menlo Park , CA , USA.
Kevin Danga Teneobio, Inc ., Menlo Park , CA , USA.
Katherine E Harrisa Teneobio, Inc ., Menlo Park , CA , USA.
Suhasini Iyera Teneobio, Inc ., Menlo Park , CA , USA.
Brett Jorgensena Teneobio, Inc ., Menlo Park , CA , USA.
Payal P Pratapa Teneobio, Inc ., Menlo Park , CA , USA.
Udaya S Rangaswamya Teneobio, Inc ., Menlo Park , CA , USA.
Harshad S Ugamraja Teneobio, Inc ., Menlo Park , CA , USA.
Omid Vafaa Teneobio, Inc ., Menlo Park , CA , USA.
Arun P Wiitab Department of Laboratory Medicine , University of California , San Francisco , CA , USA.ORCID 0000-0002-7465-6964
Wim van Schootena Teneobio, Inc ., Menlo Park , CA , USA.
Roland Buelowa Teneobio, Inc ., Menlo Park , CA , USA.
Shelley Force Aldreda Teneobio, Inc ., Menlo Park , CA , USA.ORCID 0000-0003-2095-7646
University of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell-recruiting bispecific antibodies (T-BsAbs) have shown potent tumor killing activity in humans, but cytokine release-related toxicities have affected their clinical utility. The use of novel anti-CD3 binding domains with more favorable properties could aid in the creation of T-BsAbs with improved therapeutic windows. Using a sequence-based discovery platform, we identified new anti-CD3 antibodies from humanized rats that bind to multiple epitopes and elicit varying levels of T-cell activation. In T-BsAb format, 12 different anti-CD3 arms induce equivalent levels of tumor cell lysis by primary T-cells, but potency varies by a thousand-fold. Our lead CD3-targeting arm stimulates very low levels of cytokine release, but drives robust tumor antigen-specific killing in vitro and in a mouse xenograft model. This new CD3-targeting antibody underpins a next-generation T-BsAb platform in which potent cytotoxicity is uncoupled from high levels of cytokine release, which may lead to a wider therapeutic window in the clinic.

Indexed as

AnimalsAnimals, Inbred StrainsAntibodies, BispecificAntibodies, MonoclonalAntigens, NeoplasmCD3 ComplexCytokinesCytotoxicity, ImmunologicFemaleHumansJurkat CellsLymphocyte ActivationMiceNeoplasmsRatsT-LymphocytesAntibodies, BispecificAntibodies, MonoclonalAntigens, NeoplasmCD3 ComplexCytokinesBCMABispecific antibodyCD3deep sequencingmultiple myelomarepertoireT cell engagerT cells

Identifiers

PMID30698484
PMCPMC6601548
OpenAlexW2914635378

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.